1951 Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients. (September 2015) - Bando, H.; Masuda, N.; Nakamura, R.; Kondo, N.; Kuroi, K.; Akiyoshi, S.; Ohtani, S.; Toshimi, T.; Inoue, K.; Yanagida, Y.; Ishiguro, H.; Shimizu, S.; et al.